US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
Generic net sales of $1.42 billion reflect strong growth from new product launch performances in Developed Markets, continued growth from complex products, and solid performance across the broader European portfolio.On Thursday, Viatris Inc. (NASDAQ:VTRS) reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis.
週四，Viatris Inc.（納斯達克：VTRS）報告了第二季度收入爲3797萬美元，略高於3777萬美元的共識，在剝離調整後的運營基礎上增長約2％。
Brands net sales reached $2.36 billion, reflecting strong growth in Greater China and the expansion of the company's portfolio in Emerging Markets and JANZ, partially offset by unfavorable channel dynamics in North America and the impact of government price regulations in Japan and Australia.
品牌淨銷售額達到23.6億美元，反映了大中華地區的強勁增長和公司在新興市場、JANZ領域的產品組合擴張，部分抵消了北美渠道動態不利和日本、澳洲政府價格監管的影響。
Related: Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs.
相關信息：諾華和維阿特斯因非法使用用於治療癌症藥物的HeLa細胞而被起訴。
Generic net sales of $1.42 billion reflect strong growth from new product launch performances in Developed Markets, continued growth from complex products, and solid performance across the broader European portfolio.
通用藥淨銷售額達到14.2億美元，反映了發達市場新產品推出表現強勁、複雜產品持續增長以及整個歐洲產品組合表現出色。
The company generated approximately $210 million in new product revenues, primarily driven by Breyna, lisdexamfetamine, and other new products globally.
公司產生了約2,100萬美元的新產品收入，主要由Breyna、左旋甲基苯丙胺和其他全球新產品推動。
The company reported adjusted EPS of $0.69, down 8% year over year, beating the consensus of $0.68.
公司報告調整後的每股收益爲0.69美元，同比下降8%，超過預期，預期爲0.68美元。
"I am pleased to report strong second quarter results in which we delivered divestiture-adjusted operational revenue growth across all segments, including strong growth in Greater China. This represents our fifth consecutive quarter of divestiture-adjusted operational revenue growth and demonstrates our ability to execute and grow our base business," said Scott Smith, CEO.
「我很高興地報告我們在第二季度實現了強勁的業績，所有業務板塊均實現了除牌調整後運營收入的增長，包括大中華區強勁增長。這是我們連續第五個季度實現除牌調整後的運營收入增長，證明了我們的執行能力和基礎業務增長能力，」首席執行官Scott Smith表示。
Guidance: Viatris says strong year-to-date performance gives it confidence in raising its outlook to approximately $500 million to $600 million in new product revenues in 2024 from prior range of $450 million to $550 million.
引導方針：維阿特斯表示，強勁的年初至今表現使其有信心將2024年的新產品收入展望提高到約5億至6億美元，之前的展望爲4.5億至5.5億美元。
Viatris expects 2024 sales of $14.6 billion – $15.1 billion versus the prior guidance of $14.98 billion – $15.48 billion and consensus of $14.956 billion.
維阿特斯預計2024年銷售額爲146億至151億美元，而之前的展望爲149.8億至154.8億美元，共識爲149.56億美元。
The company expects 2024 adjusted EPS of $2.58 – $2.73, versus the prior guidance of $2.66 – $2.81 and the consensus of $2.73.
該公司預計2024年調整後的每股收益爲2.58美元至2.73美元，而之前的展望爲2.66美元至2.81美元，共識爲2.73美元。
Price Action: VTRS stock is up 5.33% at $11.97 at last check Thursday.
股票價格行動：截至星期四最後一次檢查，VTRS股價上漲5.33%，至11.97美元。
Illustration of Phrama lab worker created with MidJourney.
藥廠實驗室工作者插圖，由MidJourney創建。
- GoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription Challenges.
- GoodRx報告第二季度業績，處方收入增加，但訂閱方面存在挑戰。
